



Sheet 1

RECEIVED
FEB 20 2002
TECH CENTER 1600 2900
09/18/98

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

4821-439

APPLICATION NO.

09/18/98

APPLICANT

FANG *et al.*

FILING DATE

November 16, 2001

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
10	AA	5,763,493	6/9/98	Ruff et al.			
	AB	5,753,712	5/19/98	Pinsker			
	AC	5,731,000	3/24/98	Ruff et al.			
	AD	5,541,231	7/30/96	Ruff et al.			
	AE	5,512,593	4/30/96	Dante			
	AF	5,447,948	9/5/95	Seibyl et al.			
	AG	5,427,798	6/27/95	Ludwig et al.			
	AH	5,358,970	10/25/94	Ruff et al.			
	AI	5,217,987	6/8/93	Berger			
	AJ	4,935,439	6/19/90	Kashman et al.			
	AK	4,935,429	6/19/90	Dackis et al.			
	AL	4,895,845	1/23/90	Seed			
	AM	4,868,344	9/19/89	Brown			
	AN	4,835,147	5/30/89	Roberts			
	AO	4,798,826	1/17/89	Peck			
	AP	4,769,027	9/6/88	Baker et al.			
	AQ	4,687,660	8/18/87	Baker et al.			
	AR	4,656,026	4/7/87	Coffman et al.			
	AS	4,571,395	2/18/86	Peck			
	AT	4,507,323	3/26/85	Stern			
	AU	4,438,138	3/20/84	Stern			
	AV	4,435,449	3/6/84	Stern			
	AW	4,425,363	1/10/84	Stern			
	AX	4,393,078	7/12/83	Peck			
	AY	4,356,165	10/26/82	Findlay et al.			
	AZ	4,355,179	10/19/82	Findlay et al.			

18	BA	4,347,382	8/31/82	Scharver			
	BB	4,347,257	8/31/82	Stern			
	BC	4,347,178	8/31/82	Findlay et al.			
	BD	4,347,177	8/31/82	Phillips			
	BE	4,347,176	8/31/82	Mehta			
	BF	4,008,719	2/22/77	Theeuwes et al.			
	BG	3,960,927	6/1/76	Metcalf et al.			
	BH	3,916,899	11/4/75	Theeuwes et al.			
	BI	3,885,046	5/20/75	Mehta			
	BJ	3,845,770	11/5/74	Theeuwes et al.			
	BK	3,819,706	6/25/74	Mehta			
	BL	3,630,200	12/28/71	Higuchi			
	BM	3,622,675	11/23/71	Koppe et al.			
	BN	3,598,123	8/10/71	Zaffaroni			
	BO	3,536,809	10/27/70	Applezweig			
19	BP	RE 33,994	7/14/92	Baker et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
18	BQ	WO 95/22324	8/24/95	PCT				
	BR	WO 94/20100	9/15/94	PCT				
	BS	WO 94/04138	3/3/94	PCT				
	BT	WO 93/21917	11/11/93	PCT				
	BU	WO 91/11184	8/8/91	PCT				
	BV	WO 92/19226	11/12/92	PCT				
	BW	WO 95/03791	2/09/95	PCT				
	BX	WO 96/39133	12/12/96	PCT				
	BY	WO 97/29735	8/21/97	PCT				
	BZ	WO 98/50044	11/12/98	PCT				
	CA	WO 99/37305	7/29/99	PCT				
	CB	0 467 488	1/22/92	EPO				
	CC	0 171 227	2/12/86	EPO				
	CD	0 118 036	9/12/84	EPO				
19	CE	977778	11/11/75	CA				

CF	977777	11/11/75	CA						
CG	63-91352	4/22/88	JP						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)									
CH	Ascher, J.A. et al., 1995, "Bupropion: a review of its mechanism of antidepressant activity", J. Clin. Psych. 56:395-401.								
CI	Bannon et al., 1998, "Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors", Science 279:77-81.								
CJ	Bischoff et al., 1984, "Affinity changes of rat striatal dopamine receptor in vivo after acute bupropion treatment", Eur. J. Pharmacol. 104:173-176.								
CK	Blondel-Hill et al., 1993, "Treatment of the chronic fatigue syndrome", Drugs 46(4):639-651.								
CL	Borowski, T.B. et al., 1993, "Amphetamine and antidepressant drug effects on GABA- and NMDA-related seizures", Brain Res. Bull. 30:607-610.								
CM	Calabrese, J.R. et al., 1991, "Treatment of depression", Primary Care 18(2):421-433.								
CN	Castaldi, G. et al., 1987, "Tartaric acid, an efficient chiral auxiliary: new asymmetric synthesis of 2-alkyl-2-arylacetic acids", J. Org. Chem. 52:3018.								
CO	Castello, R.A. and Mattocks, A.M., J. Pharm. Sci. 51(2):106-108 (1962).								
CP	Charney, D.S. et al., 1983, "Monoamine receptor sensitivity and depression: clinical studies of antidepressant effects on serotonin and noradrenergic function," Psychopharmacol. Bull. 19(3):490.								
CQ	Clay et al., 1988, "Clinical and neuropsychological effects of the novel antidepressant bupropion", Psychopharmacol. Bull. 24(1):143-148.								
CR	Conners, K.C. et al., 1996, "Bupropion hydrochloride in attention deficit disorder with hyperactivity", J. Am. Acad. Child Adolesc. Psychiatr. 34(10):1314-1321.								
CS	Cooke C.E., 1997, "Therapeutic advances in the treatment of cigarette addiction", J. Pharmacy Practice 10(5):329-337.								
CT	Cooper, B.R. et al., 1994, "Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin®) are mediated by a noradrenergic mechanism", Neuropsychopharmacology 11(2):133-141.								
CU	Cooper, T.B. et al., Analytical psychopharmacology: NY State Psychiatric Institute pp. 1-3.								
CV	Coutts, R.T. & Baker, G.B., 1989, "Implications of chirality and geometric isomerisms in some psychoactive drugs and their metabolites", Chirality 1:99-120.								
CW	Crenshaw et al., 1987, "Pharmacological modification of psychosexual dysfunction", J. Sex. Marital Ther. 13(4):239-252.								
CX	Cusack, B. et al., 1994, "Binding of antidepressants to human brain receptors: focus on newer generation compounds", Psychopharmacol. 114:559-565.								
CY	Davidson et al., 1994, "Bupropion in chronic low back pain", J. Clin. Psychiatry 55(8):362.								

10	CZ	Dilsaver, S.C. et al., 1992, "The efficacy of bupropion in winter depression: results of an open trial", J. Clin. Psychiatry 53(7):252-255.
	DA	Eliel, E.L., 1962, Stereochemistry of Carbon Compounds, McGraw-Hill, NY.
	DB	Ferris, R.M. et al., 1983, "Studies of bupropion's mechanism of antidepressant activity", J. Clin. Psychiatry 44(5):74-78.
	DC	Ferris & Beaman, 1983, "Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic β -adrenergic, serotonergic (5-HT ₂), α_2 -adrenergic, imipramine and dopaminergic receptors in brain", Neuropharmacol. 22(1):1257-1267.
	DD	Ferry, L.H. et al, 1992, "Enhancement of smoking cessation using the anti-depressant bupropion hydrochloride" (abstract) Circulation 86:671.
	DE	Ferry, L.H. et al., 1994, "Efficacy of bupropion for smoking cessation in non-depressed smokers," J. Addict. Dis. 13:A9.
	DF	Fisher, R.S., 1989, "Animal models of the epilepsies", Brain Res. Reviews 14:245-278.
	DG	Foot et al., 1984, "Proconvulsant effect of morphine on seizures induced by pentylentetrazol in the rat", 105:179-184.
	DH	Garland et al., 1998, "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats", J. Psychopharmacology 12(4):385-395.
	DI	Goetz et al., 1984, "Bupropion in Parkinson's Disease," 34:1092-4.
	DJ	Goodnick, P.J., 1994, "Pharmacokinetic optimisation of therapy with newer antidepressants", Clin. Pharmacokinet. 27(4):307-330.
	DK	Goodnick, P.J. & Sandoval, R., 1993, "Psychotropic treatment of depression: results of an open trial", J. Clin. Psych. 54(1):13-20.
	DL	Green, A.R. & Murray, T.K., 1989, "A simple intravenous infusion method in rodents for determining the potency of anticonvulsants acting through GABAergic mechanisms", J. Pharm. Pharmacol. 41:879-880.
	DM	Grimes et al., 1996, "Spontaneous orgasm with the combined use of bupropion and sertraline", Soc. Biol. Psych. 40:1184-1185.
	DN	Handbook of Pharmaceutical Excipients, 2nd ed., Wade and Willer eds., pp. 257-259 (1994).
	DO	Hsyu, P.H. et al., 1997, "Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers", J. Clin. Pharmacol. 37(8):737-743.
	DP	Hsyu, P.H. et al., 10 November 1997 Chemical Abstracts 127(19): Abstract no. 257089; Columbus, Ohio.
	DQ	Janowsky, A., et al., J. Neurochem. 46:1272-1276 (1986).
	DR	Kelley, J.L. et al., 1996, "(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake", J. Med. Chem. 39:347-349.

10	DS	Ketter, T.A. et al., 1995, "Carbamazepine but not valproate induces bupropion metabolism", J. Clin. Psychopharmacol. 15(5):327-333.
	DT	Laizure, S.C. et al., 1985, "Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose", Clin. Pharmacol. Ther. 38:586-589.
	DU	Lief, H.I., 1996, "Bupropion treatment of depression to assist smoking cessation", Am. J. Psychiatry 153(3):442.
	DV	Little, K.Y. et al., 1993, "[¹²⁵ I]RTI-55 binding to cocaine-sensitive dopaminergic and serotonergic uptake sites in the human brain", J. Neurochem. 61:1996-2006.
	DW	Martin, P. et al., 1990, "Antidepressant Profile of Bupropion and Three Metabolites in Mice," Pharmacopsychiatry 23:187-194.
	DX	McNamee et al., 1986, "Stimulation of substrate oxidation in rat hepatic mitochondria following pretreatment with appetite modifying drugs", J. Pharm. Pharmacol. 37:147.
	DY	Merskey, H., 1965, "The effect of chronic pain upon the response to noxious stimuli by psychiatric patients," J. Psychosom. Res. 8:405-419.
	DZ	Michell, G.F. et al., 1989, "Effect of bupropion on chocolate craving", Am. J. Psychiatry 146(1):119-120.
	EA	Michell, G.F. et al., 1989, "Dr. Mitchell and associates reply", Am. J. Psychiatry 146(8):1089.
	EB	Moisset, B., et al., Brain Res. 92:157-164 (1975).
	EC	Moret, C. & Brile, M., 1988, "Sensitizing of the response of 5-HT autoreceptors to drugs modifying synaptic availability of 5-HT", 27(1):43-49.
	ED	Musso et al., 1993, "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion", Chirality 5:495-500.
	EE	Musso et al., 1997, "Synthesis and Evaluation of the Anticonvulsant Activity of a Series of 2-Amino-Phenyl-1-Propanols Derived from the Metabolites of the Antidepressant Bupropion," Bioorganic & Medical Chemistry Letters, Vol. 7 No 1, pp 1-6, 1997.
	EF	Neurology, Official Journal of American Academy of Neurology, August 1984, volume 34, Number 8
	EG	Nomikos et al., 1992, "Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum", Neuropsychopharmacology 7(1):7-14.
	EH	Nutt, D.J. et al., 1981, "Studies on the postictal rise in seizure threshold, " Eur. J. Pharmacol. 71:287-295.
	EI	Nutt, D.J. Et al., 1980, "On the measurement in rats of the convulsant effect of drugs and the changes which follow electroconvulsive shock," Neuropharmacology 19:1017-1023.
	EJ	Olsen et al., 1985, "Benzodiazepine/γ-aminobutyric acid receptor deficit in the midbrain of the seizure-susceptible gerbil", PNAS USA 82:6701-6705.
11	EK	Pearlstein et al., 1997, "Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder", J. Clin. Psychopharmacol. 17(4):261-266.

109	EL	Perovic, S. and Mueller, W.E.G., Brain Res. 92:157-164 (1995)
	EM	Physician's Desk Reference®, (1998) pages 1120-1127.
	EN	Popli, A.P. et al., 1994, "Antidepressant-associated seizures", J. Clin. Psych. 55(6):267.
	EO	Popli, A. et al., 1995, "Bupropion and anticonvulsant drug interactions", Annals of Clin. Psychiatr. 7(2):99-101.
	EP	Posner, J. et al., 1985, "The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses", Eur. J. Clin. Pharmacol. 29:97-103.
	EQ	Potter, W.Z. & Manji, H.K., 1990, "Antidepressants, metabolites, and apparent drug resistance", Clin. Neuropharmacol. 13(1):S45-S53.
	ER	Remingtons: The Practice of the Science and Pharmacy, 19th ed., Gennaro, ed., p. 1625 (1995).
	ES	Rose, J.E., 1996, "Nicotine addiction and treatment", Annu. Rev. Med. 47:493-507.
	ET	Rosenstein, D.L. et al., 1993, "Seizures associated with antidepressants: a review", J. Clin. Psychiatry 54(8):289-299.
	EU	Rudorfer, M.V. et al., 1994, "Comparative tolerability profiles of the newer versus older antidepressants", Drug Safety 10(1):18-46.
	EV	Schroeder, D.H., 1983, "Metabolism and kinetics of bupropion", J. Clin. Psychiatr. 44(5):79-81.
	EW	Schroedger, D.H. et al., 1979, "The isolation and identification of some basic urinary metabolites of bupropion - HCL in man", The Pharmacologist 21(3):191.
	EX	SCRIP Bupropion Sustained Release (SR) for Smoking Cessation, 12/18/96.
	EY	SCRIP Itraconazole for 'pulse' dosing of onychomycosis, 12/18/96.
	EZ	Scrip's New Product Review, No. 50 Bupropion, PJB Publications: United Kingdom, August, 1990.
	FA	Stathis, M. et al., 1995, "Rate of binding of various inhibitors at the dopamine transporter in vivo", Psychopharmacol. 119:376-384.
	FB	Storrow, A.B., 1994, "Bupropion overdose and seizure", Am. J. Emerg. Med. 12:183-184.
	FC	Suckow, R.F. et al., 1986, "Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs", Drug Metab. Disposit. 14(6):692-697.
	FD	Suckow, R.F. et al., 1997, "Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography", Biomedical Chromatog. 11:174-179.
	FE	Sulser, F., 1983, "Molecular mechanisms in antidepressant action," Psychopharmacol. Bull. 19(3):300.
	FF	Sweet, R.A. et al., 1995, "Pharmacokinetics of single- and multiple- dose bupropion in elderly patients with depression", J. Clin. Pharmacol. 35:876-884.
110	FG	Testa B. and Trager, W.F., 1990, "Racemates Versus Enantiomers in Drug Development: Dogmatism or Pragmatism?" Chirality 2:129-133.

	FH	Vassout, A. et al. (1993) "Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants", J. Receptor Res. 13(1-4):341-354.
	FI	Ward, N.G. (1990) <u>The Management of Pain</u> , Second Edition, Vol. 1, Chapter 18 (eds.) Bonica, J.J. pp. 310-319.
	FJ	Ward, R. et al. (1971) "Asymmetric audiogenic seizures in mice: a possible analogue of focal epilepsy", Brain Res. 31:207-210.
	FK	Welch, R.M. et al. (1987) "Pharmacological significance of the species differences in bupropion metabolism", Nenobiotica 17(3):287-298.
	FL	Willen, S.H. (1972) <u>Tables of Resolving Agents and Optical Resolutions</u> , Univ. of Notre Dame Press, Notre Dame, IN.
	FM	Wright et al. (1985) "Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects", J. Clin. Psych. 46(1):22-25.
	FN	Zarrindast et al. (1988) "Anorectic and behavioral effects of bupropion", Gen. Pharmacology 19(2):201-204.
EXAMINER		DATE CONSIDERED 9/20/03
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO.		APPLICATION NO.	
				4821-439		09/987,931	
				APPLICANT FANG et al.			
				FILING DATE		GROUP	
				November 16, 2001		1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
FO	✓	Adeoye et al. "Bupropion Plasma Concentration and Antidepressant response in elderly patients: A Prospective, Randomized, Double-Blind Study" Int. J. Geriatr. Psychopharmacol (2000) pg. 132, col. 2, paragraph 3					
FP	✓	Pollock B. G. et al. "Bupropion Plasma Levels and CYP2D6 Phenotype" Ther. Drug Monit. (1996), 18 (5), pp. 581-585					
FQ	✓	Perumal A.S. et al. "Down-Regulation of Beta-Receptors by Bupropion and its Major Metabolite in Mouse Brain" Neuropharmacology (1986), 25 (12), 1323-6					
EXAMINER				DATE CONSIDERED			
				9/20/03			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED

JUN 26 2002

TECH CENTER 1600/2900